The potential consequences for cancer care and cancer research of Brexit

Peter Selby; Mark Lawler; Richard Baird; Ian Banks; Patrick Johnston; Paul Nurse

doi:10.3332/ecancer.2017.ed63

The potential consequences for cancer care and cancer research of Brexit

Ecancermedicalscience. 2017 Feb 24:11:ed63. doi: 10.3332/ecancer.2017.ed63. eCollection 2017.

Authors

Peter Selby¹, Mark Lawler², Richard Baird³, Ian Banks⁴, Patrick Johnston⁵, Paul Nurse⁶

Affiliations

¹ joint first authors; University of Leeds, Section of Oncology and Clinical Research, Cancer Research Building, St James's University Hospital, Beckett Street, LEEDS LS9 7TF, UK; Association of Cancer Physicians (UK); European Cancer Concord.
² joint first authors; Translational Cancer Genomics, Centre for Cancer Research and Cell Biology, Queens University Belfast, University Road, Belfast, BT7 1NN, UK; Research and Innovation, European Cancer Concord.
³ Association of Cancer Physicians (UK); Breast Cancer Therapeutics, Cambridge Breast Cancer Research Unit, UK.
⁴ Patient Advocacy, European Cancer Concord.
⁵ Queens University Belfast, University Road, Belfast, BT7 1NN, UK.
⁶ Francis Crick Institute, 1 Midland Rd, Kings Cross, London, NW1 1AT, UK.

Abstract

Following the UK "Brexit" vote in June 2016, there are many uncertainties and risks for cancer research and cancer care in the UK. These are summarised and the importance of sustained engagement and influence from the cancer community on UK governments is emphasised.

Keywords: Brexit; European Union; cancer care; cancer research.

Publication types

Editorial

Grants and funding

RP-PG-0707-10101/DH_/Department of Health/United Kingdom